Picture Swiss Biotech Association Swiss Biotech Days 2025 SBD25 Basel 650x100px

Product › Details

Concor®

	Next higher product group	bisoprolol (INN)
	Status	1994-01-01 sales existent
	Status	1998-01-01 sales existent
	Organisation	Merck (DE) (Group)
	Organisation 2	Merck (DE)
	Group	Merck (DE) (Group)

Record changed: 2023-07-10

Picture Berlin Partner Events RegMed Forum 2025 HealthCapital 650x200px

More documents for cardiovascular drug

[1] Idorsia Ltd.. (12/20/24). "Press Release: Idorsia Provides Update on the Exclusive Negotiations for the Global Rights to Aprocitentan". Allschwil....
[2] Idorsia Ltd.. (11/27/24). "Press Release: Idorsia Enters into Exclusive Negotiations for Global Rights to Aprocitentan". Allschwil....
[3] Roivant Sciences GmbH. (9/10/24). "Press Release: Roivant Unveils New Pipeline Program Mosliciguat, a Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator". Basel, London & New York, NY....
[4] Evotec SE. (6/24/24). "Press Release: beLAB1407 to Develop Novel Approach for Cardiovascular Diseases". Hamburg....
[5] Evotec SE. (4/30/24). "Press Release: Bayer and Evotec Collaborate to Advance Precision Cardiology". Berlin & Hamburg....
[6] Idorsia Ltd.. (3/20/24). "Press Release: US FDA Approves Idorsia’s Once-daily Tryvio (aprocitentan) – the First and Only Endothelin Receptor Antagonist for the Treatment of High Blood Pressure Not Adequately Controlled in Combination with other Antihy...
[7] Idorsia Ltd.. (3/18/24). "Press Release: Idorsia and Viatris Successfully Close the Transaction for the Global Research and Development Collaboration". Allschwil....
[8] Idorsia Ltd.. (2/28/24). "Press Release: Idorsia and Viatris Enter into a Significant Global Research and Development Collaboration". Allschwil....
[9] SanReno Therapeutics. (1/5/24). "Press Release: SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease". Shanghai....
[10] Roche. (7/24/23). "Press Release: Roche Enters Partnership with Alnylam to Co-develop and Co-commercialise RNAi Therapeutic Zilebesiran to Treat Hypertension in Patients with High Cardiovascular Risk". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)